SciClone Starts Clinical Trials for Two China Portfolio Products

SciClone Pharma of the US announced two clinical trial developments for its portfolio of in-licensed products aimed at the China market. The company's lead product, Zadaxin, an immune system booster, started a Phase III China trial in patients with sepsis. Currently, Zadaxin is used as an adjuvant to treat Hepatitis B or C. The company has also treated the first patient in a Taiwan Phase I trial of PT-112, a platinum-based chemotherapy that has first-in-class potential, according to SciClone. More details.... Stock Symbol: (NSDQ: SCLN) Share this with colleagues: // //